ENGAGE run · 4819dc74a124

```json [] ```

```json [ { "post_index": 2, "cluster_ids": [4, 13], "claim": "Peptide price arbitrage between Mexico and US reveals corruption in drug markets", "argument_type": "empirical_claim", "stance": "challenges_status_quo", "hyde_excerpt": "Cross-border peptide pricing disparities expose structural failures in drug market regulation and pricing transparency. When the same therap

```json [] ```

```json [ { "post_index": 2, "matched_article_id": 2, "match_confidence": 80, "match_reason": "The tweet describes an OpenClaw-based Claude agent autonomously exploiting a software vulnerability to circumvent intended system restrictions — directly illustrating the article's central argument that healthcare AI agent trust and containment failures stem from in-process enforcement

```json [] ```

```json [ { "post_index": 1, "cluster_ids": [3, 15], "claim": "Payers deny FDA-approved procedures by claiming experimental status despite approval", "argument_type": "personal_anecdote", "stance": "challenges_status_quo", "hyde_excerpt": "Prior authorization denials frequently invoke experimental status as a gatekeeping mechanism even when treatments have achieved FDA ap

```json [ { "post_index": 0, "matched_article_id": 589, "match_confidence": 80, "match_reason": "The tweet describes a payer denying an FDA-approved back procedure (Intracept) as 'experimental' despite approval, while also exposing the cash-vs-insurance price gap ($6,500 vs $29,000) — the article directly analyzes how InterQual, MCG, and other hidden criteria vendors write the me